By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Clovis Oncology 

1871 Folsom Street

Boulder  Colorado  80302  U.S.A.
Phone: n/a Fax: n/a


Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.


April 20, 2009


Founders: Patrick Mahaffy, and Erle Mast

CEO and Co-founder: Patrick Mahaffy

CMO (Medical): Lindsey Rolfe


Please click here for Clovis Oncology job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Clovis Oncology
Symbol: CLVS

Company News
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib 10/7/2016 7:57:10 AM
Clovis Oncology (CLVS) Announces Rucaparib Data Presentations At ESMO 2016 Congress 9/28/2016 11:50:15 AM
Clovis Oncology (CLVS) (Once Again) Becomes a Takeover Topic, But Some Wonder Whether It's All Hype 9/23/2016 7:53:02 AM
What's PARP? Meet Two of Biotech's Newest M&A Targets: Tesaro (TSRO) and Clovis Oncology (CLVS) 9/15/2016 6:33:52 AM
Clovis Oncology (CLVS) Stock Jumps as FDA Skips Review Panel for New Cancer Drug 9/9/2016 5:50:31 AM
Clovis Oncology (CLVS) Rockets as FDA Agrees to Priority Review of Rucaparib NDA 8/24/2016 6:10:19 AM
Clovis Oncology (CLVS) Announces Q2 2016 Operating Results and Corporate Update 8/9/2016 10:52:19 AM
7 Biotech Stocks Investors Should Keep Their Eye On in 2017 8/3/2016 6:51:13 AM
Clovis Oncology (CLVS) To Announce Second Quarter 2016 Financial Results And Host Webcast Conference Call On August 8 7/27/2016 9:25:02 AM
ASCO2016: Clovis Oncology (CLVS) Presents Data From Phase II Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting 6/6/2016 3:34:17 PM